Physician profile
Won Bae Choe
NPI 1104955194
$1,342.35
in general payments reported to CMS, 2019-2025
18 companies · $192 in 2025
The $192 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $411 · 2020: $24.87 · 2021: $181 · 2022: $173 · 2023: $99.40 · 2024: $262 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $553.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $251.52 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $230.29 | 2019-2022 | |
| Lilly USA, LLC | $169.59 | 2019-2024 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $157.23 | 2023-2024 | Arexvy, Trelegy Ellipta |
| Abbvie INC. | $108.56 | 2019-2025 | |
| Gilead Sciences, INC. | $79.37 | 2021-2023 | |
| Amgen INC. | $72.02 | 2022-2024 | Repatha, Otezla |
| Nestle Healthcare Nutrition INC. | $47.09 | 2021 | |
| Sanofi Pasteur INC. | $42.29 | 2023-2025 | |
| Boston Scientific Corporation | $30.15 | 2024-2025 | Wavewriter Alpha Prime 16 |
| Merck Sharp & Dohme LLC | $24.29 | 2025 | Capvaxive, Gardasil 9 |
| Vbi Vaccine (Delaware) INC. | $23.46 | 2022 | |
| Aimmune Therapeutics, INC. | $20.97 | 2024 | |
| Novo Nordisk INC | $20.05 | 2021 | |
| Viiv Healthcare Company | $18.61 | 2025 | Apretude |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $16.30 | 2019 | |
| Arbor Pharmaceuticals, INC. | $16.06 | 2021 | |
| Allergan, INC. | $14.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Won Bae Choe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.